{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:46:22Z","timestamp":1794465982669,"version":"4.9.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41577-019-0182-z","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T10:26:28Z","timestamp":1560507988000},"page":"614-625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":274,"title":["Interferon-\u03bb orchestrates innate and adaptive mucosal immune responses"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-0836","authenticated-orcid":false,"given":"Liang","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7528-981X","authenticated-orcid":false,"given":"Daniel","family":"Schnepf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7057-6177","authenticated-orcid":false,"given":"Peter","family":"Staeheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"key":"182_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko, S. V. et al. IFN-\u03bbs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69\u201377 (2003).","journal-title":"Nat. Immunol."},{"key":"182_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63\u201368 (2003).","journal-title":"Nat. Immunol."},{"key":"182_CR3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503\u2013514 (2012).","journal-title":"Immunity"},{"key":"182_CR4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.180.4.2474","volume":"180","author":"N Ank","year":"2008","unstructured":"Ank, N. et al. An important role for type III interferon (IFN-\u03bb\/IL-28) in TLR-induced antiviral activity. J. Immunol. 180, 2474\u20132485 (2008).","journal-title":"J. Immunol."},{"key":"182_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2018.10.007","volume":"56","author":"E Andreakos","year":"2018","unstructured":"Andreakos, E., Zanoni, I. & Galani, I. E. Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control. Curr. Opin. Immunol. 56, 67\u201375 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"182_CR6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.chom.2017.09.010","volume":"22","author":"SM Best","year":"2017","unstructured":"Best, S. M. & Robertson, S. J. IFN-\u03bb: the key to norovirus\u2019s secret hideaway. Cell Host Microbe 22, 427\u2013429 (2017).","journal-title":"Cell Host Microbe"},{"key":"182_CR7","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1074\/jbc.R117.777102","volume":"292","author":"SV Kotenko","year":"2017","unstructured":"Kotenko, S. V. & Durbin, J. E. Contribution of type III interferons to antiviral immunity: location, location, location. J. Biol. Chem. 292, 7295\u20137303 (2017).","journal-title":"J. Biol. Chem."},{"key":"182_CR8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.tim.2017.10.010","volume":"26","author":"TJ Nice","year":"2018","unstructured":"Nice, T. J., Robinson, B. A. & Van Winkle, J. A. The role of interferon in persistent viral infection: insights from murine norovirus. Trends Microbiol. 26, 510\u2013524 (2018).","journal-title":"Trends Microbiol."},{"key":"182_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/gene.2016.24","volume":"17","author":"S Chinnaswamy","year":"2016","unstructured":"Chinnaswamy, S. Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections. Genes Immun. 17, 265\u2013275 (2016).","journal-title":"Genes Immun."},{"key":"182_CR10","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.immuni.2017.04.027","volume":"46","author":"BA Robinson","year":"2017","unstructured":"Robinson, B. A. & Nice, T. J. You can breathe easy: IFN\u03bb handles flu without triggering a damaging inflammatory response. Immunity 46, 768\u2013770 (2017).","journal-title":"Immunity"},{"key":"182_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2017.00119","volume":"8","author":"M Syedbasha","year":"2017","unstructured":"Syedbasha, M. & Egli, A. Interferon \u03bb: modulating immunity in infectious diseases. Front. Immunol. 8, 119 (2017).","journal-title":"Front. Immunol."},{"key":"182_CR12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.it.2018.08.008","volume":"39","author":"AI Wells","year":"2018","unstructured":"Wells, A. I. & Coyne, C. B. Type III interferons in antiviral defenses at barrier surfaces. Trends Immunol. 39, 848\u2013858 (2018).","journal-title":"Trends Immunol."},{"key":"182_CR13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3389\/fimmu.2017.01661","volume":"8","author":"I Zanoni","year":"2017","unstructured":"Zanoni, I., Granucci, F. & Broggi, A. Interferon (IFN)-\u03bb takes the helm: immunomodulatory roles of type III IFNs. Front. Immunol. 8, 1661 (2017).","journal-title":"Front. Immunol."},{"key":"182_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/jir.2018.0046","volume":"39","author":"A Lasfar","year":"2018","unstructured":"Lasfar, A., Zloza, A., Silk, A. W., Lee, L. Y. & Cohen-Solal, K. A. Interferon \u03bb: toward a dual role in cancer. J. Interferon Cytokine Res. 39, 22\u201329 (2018).","journal-title":"J. Interferon Cytokine Res."},{"key":"182_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","volume":"43","author":"HM Lazear","year":"2015","unstructured":"Lazear, H. M., Nice, T. J. & Diamond, M. S. Interferon-\u03bb: immune functions at barrier surfaces and beyond. Immunity 43, 15\u201328 (2015).","journal-title":"Immunity"},{"key":"182_CR16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3389\/fimmu.2017.00749","volume":"8","author":"S Lee","year":"2017","unstructured":"Lee, S. & Baldridge, M. T. Interferon-\u03bb: a potent regulator of intestinal viral infections. Front. Immunol. 8, 749 (2017).","journal-title":"Front. Immunol."},{"key":"182_CR17","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s13238-017-0503-6","volume":"9","author":"Y Sun","year":"2018","unstructured":"Sun, Y., Jiang, J., Tien, P., Liu, W. & Li, J. IFN-\u03bb: a new spotlight in innate immunity against influenza virus infection. Protein Cell 9, 832\u2013837 (2018).","journal-title":"Protein Cell"},{"key":"182_CR18","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.3390\/ijms20061445","volume":"20","author":"ML Stanifer","year":"2019","unstructured":"Stanifer, M. L., Pervolaraki, K. & Boulant, S. Differential regulation of type I and type III interferon signaling. Int. J. Mol. Sci. 20, E1445 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"182_CR19","doi-asserted-by":"crossref","first-page":"7232361","DOI":"10.1155\/2017\/7232361","volume":"2017","author":"J Bruening","year":"2017","unstructured":"Bruening, J., Weigel, B. & Gerold, G. The role of type III interferons in hepatitis C virus infection and therapy. J. Immunol. Res. 2017, 7232361 (2017).","journal-title":"J. Immunol. Res."},{"key":"182_CR20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fimmu.2016.00628","volume":"7","author":"M Boisvert","year":"2016","unstructured":"Boisvert, M. & Shoukry, N. H. Type III interferons in hepatitis C virus infection. Front. Immunol. 7, 628 (2016).","journal-title":"Front. Immunol."},{"key":"182_CR21","first-page":"796461","volume":"2015","author":"B Liu","year":"2015","unstructured":"Liu, B., McGilvray, I. & Chen, L. IFN-\u03bb: a new class of interferon with distinct functions-implications for hepatitis C virus research. Gastroenterol. Res. Pract. 2015, 796461 (2015).","journal-title":"Gastroenterol. Res. Pract."},{"key":"182_CR22","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jmv.24227","volume":"87","author":"DB Olmedo","year":"2015","unstructured":"Olmedo, D. B., Cader, S. A. & Porto, L. C. IFN- gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. J. Med. Virol. 87, 1702\u20131715 (2015).","journal-title":"J. Med. Virol."},{"key":"182_CR23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000369902","volume":"7","author":"SJ Griffiths","year":"2015","unstructured":"Griffiths, S. J., Dunnigan, C. M., Russell, C. D. & Haas, J. G. The role of interferon-\u03bb locus polymorphisms in hepatitis C and other infectious diseases. J. Innate Immun. 7, 231\u2013242 (2015).","journal-title":"J. Innate Immun."},{"key":"182_CR24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000369973","volume":"7","author":"S Mihm","year":"2015","unstructured":"Mihm, S. Activation of type I and type III interferons in chronic hepatitis C. J. Innate Immun. 7, 251\u2013259 (2015).","journal-title":"J. Innate Immun."},{"key":"182_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000017","volume":"4","author":"C Sommereyns","year":"2008","unstructured":"Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-\u03bb (IFN-\u03bb) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLOS Pathog. 4, e1000017 (2008).","journal-title":"PLOS Pathog."},{"key":"182_CR26","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1128\/JVI.02764-13","volume":"88","author":"A Reuter","year":"2014","unstructured":"Reuter, A. et al. Antiviral activity of \u03bb interferon in chickens. J. Virol. 88, 2835\u20132843 (2014).","journal-title":"J. Virol."},{"key":"182_CR27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.intimp.2004.01.016","volume":"4","author":"AL Gurney","year":"2004","unstructured":"Gurney, A. L. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int. Immunopharmacol. 4, 669\u2013677 (2004).","journal-title":"Int. Immunopharmacol."},{"key":"182_CR28","doi-asserted-by":"crossref","first-page":"eaan5357","DOI":"10.1126\/sciimmunol.aan5357","volume":"2","author":"V Espinosa","year":"2017","unstructured":"Espinosa, V. et al. Type III interferon is a critical regulator of innate antifungal immunity. Sci. Immunol. 2, eaan5357 (2017). This study highlights the importance of IFN-\u03bb during antifungal immunity and shows that neutrophils have a key role in the response.","journal-title":"Sci. Immunol."},{"key":"182_CR29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2017.03.015","volume":"153","author":"MT Chiriac","year":"2017","unstructured":"Chiriac, M. T. et al. Activation of epithelial signal transducer and activator of transcription 1 by interleukin 28 controls mucosal healing in mice with colitis and is increased in mucosa of patients with inflammatory bowel disease. Gastroenterology 153, 123\u2013138 (2017).","journal-title":"Gastroenterology"},{"key":"182_CR30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3389\/fimmu.2017.01302","volume":"8","author":"TA Selvakumar","year":"2017","unstructured":"Selvakumar, T. A. et al. Identification of a predominantly interferon-\u03bb-induced transcriptional profile in murine intestinal epithelial cells. Front. Immunol. 8, 1302 (2017).","journal-title":"Front. Immunol."},{"key":"182_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001758","volume":"12","author":"S Ding","year":"2014","unstructured":"Ding, S., Khoury-Hanold, W., Iwasaki, A. & Robek, M. D. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLOS Biol. 12, e1001758 (2014).","journal-title":"PLOS Biol."},{"key":"182_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004782","volume":"11","author":"T Mahlakoiv","year":"2015","unstructured":"Mahlakoiv, T., Hernandez, P., Gronke, K., Diefenbach, A. & Staeheli, P. Leukocyte-derived IFN-\u03b1\/beta and epithelial IFN-\u03bb constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLOS Pathog. 11, e1004782 (2015). This article shows that type I and type III IFNs act on separate cell types in the intestinal mucosa.","journal-title":"PLOS Pathog."},{"key":"182_CR33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000151","volume":"4","author":"M Mordstein","year":"2008","unstructured":"Mordstein, M. et al. Interferon-\u03bb contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLOS Pathog. 4, e1000151 (2008).","journal-title":"PLOS Pathog."},{"key":"182_CR34","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1128\/JVI.00272-10","volume":"84","author":"M Mordstein","year":"2010","unstructured":"Mordstein, M. et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84, 5670\u20135677 (2010).","journal-title":"J. Virol."},{"key":"182_CR35","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ni.3212","volume":"16","author":"A Wack","year":"2015","unstructured":"Wack, A., Terczynska-Dyla, E. & Hartmann, R. Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16, 802\u2013809 (2015).","journal-title":"Nat. Immunol."},{"key":"182_CR36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.33354","volume":"7","author":"J Klinkhammer","year":"2018","unstructured":"Klinkhammer, J. et al. IFN-\u03bb prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. eLife 7, e33354 (2018). This study shows that IFN-\u03bb has a previously overlooked role in the upper airways, where it reduces viral transmission and the spread of respiratory viruses to the lungs.","journal-title":"eLife"},{"key":"182_CR37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ng2047","volume":"39","author":"DT Odom","year":"2007","unstructured":"Odom, D. T. et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat. Genet. 39, 730\u2013732 (2007).","journal-title":"Nat. Genet."},{"key":"182_CR38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1189\/jlb.0812395","volume":"93","author":"H Dickensheets","year":"2013","unstructured":"Dickensheets, H., Sheikh, F., Park, O., Gao, B. & Donnelly, R. P. Interferon-\u03bb (IFN-\u03bb) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J. Leukoc. Biol. 93, 377\u2013385 (2013).","journal-title":"J. Leukoc. Biol."},{"key":"182_CR39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015200","volume":"5","author":"J Diegelmann","year":"2010","unstructured":"Diegelmann, J. et al. Comparative analysis of the \u03bb-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLOS ONE 5, e15200 (2010).","journal-title":"PLOS ONE"},{"key":"182_CR40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","volume":"44","author":"SE Doyle","year":"2006","unstructured":"Doyle, S. E. et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44, 896\u2013906 (2006).","journal-title":"Hepatology"},{"key":"182_CR41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cei.12368","volume":"177","author":"K Lind","year":"2014","unstructured":"Lind, K., Svedin, E., Utorova, R., Stone, V. M. & Flodstrom-Tullberg, M. Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. Clin. Exp. Immunol. 177, 687\u2013695 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"182_CR42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","volume":"52","author":"AJ Muir","year":"2010","unstructured":"Muir, A. J. et al. Phase 1b study of pegylated interferon \u03bb 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52, 822\u2013832 (2010).","journal-title":"Hepatology"},{"key":"182_CR43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087906","volume":"9","author":"P Hermant","year":"2014","unstructured":"Hermant, P. et al. Human but not mouse hepatocytes respond to interferon-\u03bb in vivo. PLOS ONE 9, e87906 (2014).","journal-title":"PLOS ONE"},{"key":"182_CR44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/03079457.2018.1556386","volume":"48","author":"A Lion","year":"2018","unstructured":"Lion, A. et al. Chicken endothelial cells are highly responsive to viral innate immune stimuli and are susceptible to infections with various avian pathogens. Avian Pathol. 48, 121\u2013134 (2018).","journal-title":"Avian Pathol."},{"key":"182_CR45","doi-asserted-by":"crossref","first-page":"284ra259","DOI":"10.1126\/scitranslmed.aaa4304","volume":"7","author":"HM Lazear","year":"2015","unstructured":"Lazear, H. M. et al. Interferon-\u03bb restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci. Transl Med. 7, 284ra259 (2015).","journal-title":"Sci. Transl Med."},{"key":"182_CR46","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00819-17","volume":"8","author":"F Douam","year":"2017","unstructured":"Douam, F. et al. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. mBio 8, e0081917 (2017).","journal-title":"mBio"},{"key":"182_CR47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/jir.2015.0169","volume":"36","author":"A Kelly","year":"2016","unstructured":"Kelly, A. et al. Immune cell profiling of IFN- response shows pDCs express highest level of IFN-R1 and are directly responsive via the JAK-STAT pathway. J. Interferon Cytokine Res. 36, 671\u2013680 (2016).","journal-title":"J. Interferon Cytokine Res."},{"key":"182_CR48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1189\/jlb.3A0215-041RR","volume":"98","author":"RA de Groen","year":"2015","unstructured":"de Groen, R. A., Groothuismink, Z. M. A., Liu, B. S. & Boonstra, A. IFN-\u03bb is able to augment TLR-mediated activation and subsequent function of primary human B cells. J. Leukoc. Biol. 98, 623\u2013630 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"182_CR49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/gene.2009.72","volume":"10","author":"K Witte","year":"2009","unstructured":"Witte, K. et al. Despite IFN-\u03bb receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10, 702\u2013714 (2009).","journal-title":"Genes Immun."},{"key":"182_CR50","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/leu.2008.263","volume":"22","author":"AJ Novak","year":"2008","unstructured":"Novak, A. J. et al. A role for IFN-\u03bb 1 in multiple myeloma B cell growth. Leukemia 22, 2240\u20132246 (2008).","journal-title":"Leukemia"},{"key":"182_CR51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004556","volume":"10","author":"A Egli","year":"2014","unstructured":"Egli, A. et al. IL-28B is a key regulator of B\u2212 and T cell vaccine responses against influenza. PLOS Pathog. 10, e1004556 (2014).","journal-title":"PLOS Pathog."},{"key":"182_CR52","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ni.3821","volume":"18","author":"A Broggi","year":"2017","unstructured":"Broggi, A., Tan, Y., Granucci, F. & Zanoni, I. IFN-\u03bb suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat.\u00a0Immunol. 18, 1084\u20131093 (2017). This paper reports that IFN-\u03bb can modulate neutrophil activity through non-conventional signalling pathways that involve the kinase JAK2.","journal-title":"Nat. Immunol."},{"key":"182_CR53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","volume":"46","author":"IE Galani","year":"2017","unstructured":"Galani, I. E. et al. Interferon-\u03bb mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness. Immunity 46, 875\u2013890 (2017). This study contributes evidence that IFN-\u03bb has a decisive role in antiviral defence of the respiratory tract by acting on airway epithelial cells and neutrophils.","journal-title":"Immunity"},{"key":"182_CR54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41590-019-0345-x","volume":"20","author":"L Ye","year":"2019","unstructured":"Ye, L. et al. Interferon-\u03bb enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat. Immunol. 20, 593\u2013601 (2019). This study indicates a novel mechanism by which IFN-\u03bb can increase adaptive antiviral immunity in the respiratory mucosa.","journal-title":"Nat. Immunol."},{"key":"182_CR55","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1084\/jem.20140995","volume":"212","author":"K Blazek","year":"2015","unstructured":"Blazek, K. et al. IFN-\u03bb resolves inflammation via suppression of neutrophil infiltration and IL-1beta production. J. Exp. Med. 212, 845\u2013853 (2015).","journal-title":"J. Exp. Med."},{"key":"182_CR56","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1102038","volume":"189","author":"Z Yin","year":"2012","unstructured":"Yin, Z. et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J. Immunol. 189, 2735\u20132745 (2012).","journal-title":"J. Immunol."},{"key":"182_CR57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1189\/jlb.0509347","volume":"86","author":"NJ Megjugorac","year":"2009","unstructured":"Megjugorac, N. J., Gallagher, G. E. & Gallagher, G. Modulation of human plasmacytoid DC function by IFN-\u03bb 1 (IL-29). J. Leukoc. Biol. 86, 1359\u20131363 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"182_CR58","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2005-10-4129","volume":"107","author":"FJD Mennechet","year":"2006","unstructured":"Mennechet, F. J. D. & Uze, G. Interferon-\u03bb-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107, 4417\u20134423 (2006).","journal-title":"Blood"},{"key":"182_CR59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1189\/jlb.3VMA0415-144R","volume":"99","author":"G Finotti","year":"2016","unstructured":"Finotti, G., Tamassia, N., Calzetti, F., Fattovich, G. & Cassatella, M. A. Endogenously produced TNF-\u03b1 contributes to the expression of CXCL10\/IP-10 in IFN-\u03bb 3-activated plasmacytoid dendritic cells. J. Leukoc. Biol. 99, 107\u2013119 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"182_CR60","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/1753425913503385","volume":"20","author":"KS O\u2019Connor","year":"2014","unstructured":"O\u2019Connor, K. S. et al. IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immun. 20, 598\u2013605 (2014).","journal-title":"Innate Immun."},{"key":"182_CR61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.gene.6364348","volume":"8","author":"WJ Jordan","year":"2007","unstructured":"Jordan, W. J. et al. Modulation of the human cytokine response by interferon \u03bb-1 (IFN-\u03bb1\/IL-29). Genes Immun. 8, 13\u201320 (2007).","journal-title":"Genes Immun."},{"key":"182_CR62","doi-asserted-by":"crossref","first-page":"E2376","DOI":"10.1073\/pnas.1424241112","volume":"112","author":"F Souza-Fonseca-Guimaraes","year":"2015","unstructured":"Souza-Fonseca-Guimaraes, F. et al. NK cells require IL-28R for optimal in vivo activity. Proc. Natl Acad. Sci. USA 112, E2376\u2013E2384 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"182_CR63","volume":"13","author":"SG Brias","year":"2018","unstructured":"Brias, S. G. et al. Interferon \u03bb is required for interferon \u03b3-expressing NK cell responses but does not afford antiviral protection during acute and persistent murine cytomegalovirus infection. PLOS ONE 13, e0197596 (2018).","journal-title":"PLOS ONE"},{"key":"182_CR64","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.humimm.2014.06.016","volume":"75","author":"MH Morrison","year":"2014","unstructured":"Morrison, M. H. et al. IFNL cytokines do not modulate human or murine NK cell functions. Hum. Immunol. 75, 996\u20131000 (2014).","journal-title":"Hum. Immunol."},{"key":"182_CR65","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4049\/jimmunol.1601430","volume":"199","author":"YS Wang","year":"2017","unstructured":"Wang, Y. S. et al. Involvement of NK cells in IL-28B-mediated immunity against influenza virus infection. J. Immunol. 199, 1012\u20131020 (2017).","journal-title":"J. Immunol."},{"key":"182_CR66","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2010-07-298976","volume":"117","author":"BS Liu","year":"2011","unstructured":"Liu, B. S., Janssen, H. L. A. & Boonstra, A. IL-29 and IFN \u03b1 differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFN \u03b3 receptor expression. Blood 117, 2385\u20132395 (2011).","journal-title":"Blood"},{"key":"182_CR67","volume":"7","author":"MQ Liu","year":"2012","unstructured":"Liu, M. Q. et al. IFN-\u03bb3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLOS ONE 7, e35902 (2012).","journal-title":"PLOS ONE"},{"key":"182_CR68","volume":"88","author":"QJ Su","year":"2018","unstructured":"Su, Q. J. et al. IFN-\u03bb4 inhibits HIV infection of macrophages through signaling of IFN-\u03bbR1\/IL-10R2 receptor complex. Scand. J. Immunol. 88, e12717 (2018).","journal-title":"Scand. J. Immunol."},{"key":"182_CR69","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.celrep.2017.06.085","volume":"20","author":"JH Lumb","year":"2017","unstructured":"Lumb, J. H. et al. DDX6 represses aberrant activation of interferon-stimulated genes. Cell Rep. 20, 819\u2013831 (2017).","journal-title":"Cell Rep."},{"key":"182_CR70","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/eji.201646519","volume":"46","author":"S Fuchs","year":"2016","unstructured":"Fuchs, S. et al. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur. J. Immunol. 46, 2639\u20132649 (2016).","journal-title":"Eur. J. Immunol."},{"key":"182_CR71","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","volume":"212","author":"AY Kreins","year":"2015","unstructured":"Kreins, A. Y. et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212, 1641\u20131662 (2015).","journal-title":"J. Exp. Med."},{"key":"182_CR72","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ni.2915","volume":"15","author":"C Odendall","year":"2014","unstructured":"Odendall, C. et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 15, 717\u2013726 (2014).","journal-title":"Nat. Immunol."},{"key":"182_CR73","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3892\/ijmm.2012.1064","volume":"30","author":"SJ Lee","year":"2012","unstructured":"Lee, S. J., Kim, W. J. & Moon, S. K. Role of the p38 MAPK signaling pathway in mediating interleukin-28A-induced migration of UMUC-3 cells. Int. J. Mol. Med. 30, 945\u2013952 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"182_CR74","doi-asserted-by":"crossref","first-page":"eaap9614","DOI":"10.1126\/sciimmunol.aap9614","volume":"2","author":"D Schnepf","year":"2017","unstructured":"Schnepf, D. & Staeheli, P. License to kill: IFN-\u03bb regulates antifungal activity of neutrophils. Sci. Immunol. 2, eaap9614 (2017).","journal-title":"Sci. Immunol."},{"key":"182_CR75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fimmu.2017.00459","volume":"8","author":"K Pervolaraki","year":"2017","unstructured":"Pervolaraki, K. et al. Type I and type III interferons display different dependency on mitogen-activated protein kinases to mount an antiviral state in the human gut. Front. Immunol. 8, 459 (2017). This study shows that non-canonical MAPK signalling is required for full antiviral protection of human intestinal epithelial cells induced by type III IFN but not by type I IFN.","journal-title":"Front. Immunol."},{"key":"182_CR76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007420","volume":"14","author":"K Pervolaraki","year":"2018","unstructured":"Pervolaraki, K. et al. Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance. PLOS Pathog. 14, e1007420 (2018).","journal-title":"PLOS Pathog."},{"key":"182_CR77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003773","volume":"9","author":"S Crotta","year":"2013","unstructured":"Crotta, S. et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLOS Pathog. 9, e1003773 (2013).","journal-title":"PLOS Pathog."},{"key":"182_CR78","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/JLB.2MIR0817-342R","volume":"103","author":"KI Arimoto","year":"2018","unstructured":"Arimoto, K. I., Miyauchi, S., Stoner, S. A., Fan, J. B. & Zhang, D. E. Negative regulation of type I IFN signaling. J. Leukoc. Biol. 103, 1099\u20131116 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"182_CR79","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.emboj.7601149","volume":"25","author":"OA Malakhova","year":"2006","unstructured":"Malakhova, O. A. et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 25, 2358\u20132367 (2006).","journal-title":"EMBO J."},{"key":"182_CR80","doi-asserted-by":"crossref","first-page":"17928","DOI":"10.1074\/jbc.M117.788877","volume":"292","author":"T Blumer","year":"2017","unstructured":"Blumer, T., Coto-Llerena, M., Duong, F. H. T. & Heim, M. H. SOCS1 is an inducible negative regulator of interferon \u03bb (IFN-\u03bb)-induced gene expression in vivo. J. Biol. Chem. 292, 17928\u201317938 (2017).","journal-title":"J. Biol. Chem."},{"key":"182_CR81","doi-asserted-by":"crossref","first-page":"33811","DOI":"10.1074\/jbc.M111.270207","volume":"286","author":"RA Piganis","year":"2011","unstructured":"Piganis, R. A. et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon \u03b1 receptor (IFNAR1)-associated tyrosine kinase Tyk2. J. Biol. Chem. 286, 33811\u201333818 (2011).","journal-title":"J. Biol. Chem."},{"key":"182_CR82","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.15252\/emmm.201606413","volume":"8","author":"S Davidson","year":"2016","unstructured":"Davidson, S. et al. IFN\u03bb is a potent anti-influenza therapeutic without the inflammatory side effects of IFN\u03b1 treatment. EMBO Mol. Med. 8, 1099\u20131112 (2016). This article introduces the concept that IFN-\u03bb might be a better therapeutic anti-influenza drug than type I IFN.","journal-title":"EMBO Mol. Med."},{"key":"182_CR83","doi-asserted-by":"crossref","first-page":"7944","DOI":"10.1073\/pnas.1100552108","volume":"108","author":"J Pott","year":"2011","unstructured":"Pott, J. et al. IFN-\u03bb determines the intestinal epithelial antiviral host defense. Proc. Natl Acad. Sci. USA 108, 7944\u20137949 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"182_CR84","volume":"12","author":"JD Lin","year":"2016","unstructured":"Lin, J. D. et al. Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PLOS Pathog. 12, e1005600 (2016).","journal-title":"PLOS Pathog."},{"key":"182_CR85","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1126\/science.aar3799","volume":"360","author":"CB Wilen","year":"2018","unstructured":"Wilen, C. B. et al. Tropism for tuft cells determines immune promotion of norovirus pathogenesis. Science 360, 204\u2013208 (2018). This study shows that norovirus persists in tuft cells and that IFN-\u03bb treatment of mice eliminates the virus from this reservoir.","journal-title":"Science"},{"key":"182_CR86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1258100","volume":"347","author":"TJ Nice","year":"2015","unstructured":"Nice, T. J. et al. Interferon-\u03bb cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347, 269\u2013273 (2015).","journal-title":"Science"},{"key":"182_CR87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.antiviral.2017.10.017","volume":"149","author":"J Rocha-Pereira","year":"2018","unstructured":"Rocha-Pereira, J. et al. Interferon \u03bb (IFN-\u03bb) efficiently blocks norovirus transmission in a mouse model. Antiviral Res. 149, 7\u201315 (2018).","journal-title":"Antiviral Res."},{"key":"182_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0416-7","author":"H Ingle","year":"2019","unstructured":"Ingle, H. et al. Viral complementation of immunodeficiency confers protection against enteric pathogens via interferon-\u03bb. Nat. Microbiol. \n                    https:\/\/doi.org\/10.1038\/s41564-019-0416-7\n                    \n                   (2019).","journal-title":"Nat. Microbiol."},{"key":"182_CR89","doi-asserted-by":"crossref","first-page":"eaau4255","DOI":"10.1126\/sciadv.aau4255","volume":"5","author":"C Good","year":"2019","unstructured":"Good, C., Wells, A. I. & Coyne, C. B. Type III interferon signaling restricts enterovirus 71 infection of goblet cells. Sci. Adv. 5, eaau4255 (2019).","journal-title":"Sci. Adv."},{"key":"182_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2019.02.007","volume":"8","author":"SH Ferguson","year":"2019","unstructured":"Ferguson, S. H. et al. Interferon-\u03bb3 promotes epithelial defense and barrier function against Cryptosporidium parvum infection. Cell. Mol. Gastroenterol. Hepatol. 8, 1\u201320 (2019). This article shows that IFN-\u03bb is also involved in host defence against infection with protozoal parasites.","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"182_CR91","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.4049\/jimmunol.1700250","volume":"199","author":"C Odendall","year":"2017","unstructured":"Odendall, C., Voak, A. A. & Kagan, J. C. Type III IFNs are commonly induced by bacteria-sensing TLRs and reinforce epithelial barriers during infection. J. Immunol. 199, 3270\u20133279 (2017).","journal-title":"J. Immunol."},{"key":"182_CR92","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tim.2014.12.003","volume":"23","author":"O Haller","year":"2015","unstructured":"Haller, O., Staeheli, P., Schwemmle, M. & Kochs, G. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol. 23, 154\u2013163 (2015).","journal-title":"Trends Microbiol."},{"key":"182_CR93","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.virusres.2011.07.011","volume":"160","author":"T Okabayashi","year":"2011","unstructured":"Okabayashi, T. et al. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 160, 360\u2013366 (2011).","journal-title":"Virus Res."},{"key":"182_CR94","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1128\/JVI.01703-09","volume":"84","author":"NA Jewell","year":"2010","unstructured":"Jewell, N. A. et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 84, 11515\u201311522 (2010).","journal-title":"J. Virol."},{"key":"182_CR95","doi-asserted-by":"crossref","first-page":"eaao0052","DOI":"10.1126\/scitranslmed.aao0052","volume":"10","author":"RB Werder","year":"2018","unstructured":"Werder, R. B. et al. PGD2\/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-\u03bb production. Sci. Transl Med. 10, eaao0052 (2018).","journal-title":"Sci. Transl Med."},{"key":"182_CR96","volume":"9","author":"TS Cohen","year":"2013","unstructured":"Cohen, T. S. & Prince, A. S. Bacterial pathogens activate a common inflammatory pathway through IFN\u03bb regulation of PDCD4. PLOS Pathog. 9, e1003682 (2013).","journal-title":"PLOS Pathog."},{"key":"182_CR97","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/eji.201847556","volume":"48","author":"S Pires","year":"2018","unstructured":"Pires, S. & Parker, D. IL-1beta activation in response to Staphylococcus aureus lung infection requires inflammasome-dependent and independent mechanisms. Eur. J. Immunol. 48, 1707\u20131716 (2018).","journal-title":"Eur. J. Immunol."},{"key":"182_CR98","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1165\/rcmb.2018-0021OC","volume":"60","author":"D Ahn","year":"2018","unstructured":"Ahn, D., Wickersham, M., Riquelme, S. & Prince, A. The effects of IFN-\u03bb on epithelial barrier function contribute to K. pneumoniae ST258 pneumonia. Am. J. Respir. Cell. Mol. Biol. 60, 158\u2013166 (2018).","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"182_CR99","first-page":"e00114","volume":"87","author":"HE Rich","year":"2019","unstructured":"Rich, H. E. et al. Interferon \u03bb inhibits bacterial uptake during influenza superinfection. Infect. Immun. 87, e00114\u201319 (2019).","journal-title":"Infect. Immun."},{"key":"182_CR100","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07993-2","volume":"10","author":"EA Caine","year":"2019","unstructured":"Caine, E. A. et al. Interferon \u03bb protects the female reproductive tract against Zika virus infection. Nat. Commun. 10, 280 (2019).","journal-title":"Nat. Commun."},{"key":"182_CR101","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nri3819","volume":"15","author":"CR Wira","year":"2015","unstructured":"Wira, C. R., Rodriguez-Garcia, M. & Patel, M. V. The role of sex hormones in immune protection of the female reproductive tract. Nat. Rev. Immunol. 15, 217\u2013230 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"182_CR102","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","volume":"34","author":"MB Fuertes","year":"2013","unstructured":"Fuertes, M. B., Woo, S. R., Burnett, B., Fu, Y. X. & Gajewski, T. F. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67\u201373 (2013).","journal-title":"Trends Immunol."},{"key":"182_CR103","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.4049\/jimmunol.1301705","volume":"192","author":"I Misumi","year":"2014","unstructured":"Misumi, I. & Whitmire, J. K. IFN-\u03bb exerts opposing effects on T cell responses depending on the chronicity of the virus infection. J. Immunol. 192, 3596\u20133606 (2014).","journal-title":"J. Immunol."},{"key":"182_CR104","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.1998.9508","volume":"252","author":"A Garcia-Sastre","year":"1998","unstructured":"Garcia-Sastre, A. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324\u2013330 (1998).","journal-title":"Virology"},{"key":"182_CR105","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.vaccine.2014.02.009","volume":"32","author":"A Morokutti","year":"2014","unstructured":"Morokutti, A., Muster, T. & Ferko, B. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. Vaccine 32, 1897\u20131900 (2014).","journal-title":"Vaccine"},{"key":"182_CR106","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.vaccine.2013.10.061","volume":"31","author":"C Mossler","year":"2013","unstructured":"Mossler, C. et al. Phase I\/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 31, 6194\u20136200 (2013).","journal-title":"Vaccine"},{"key":"182_CR107","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/blood-2008-11-190520","volume":"113","author":"MP Morrow","year":"2009","unstructured":"Morrow, M. P. et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113, 5868\u20135877 (2009).","journal-title":"Blood"},{"key":"182_CR108","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/vim.2017.0033","volume":"30","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. et al. Optimized DNA vaccine enhanced by adjuvant IL28B induces protective immune responses against herpes simplex virus type 2 in mice. Viral Immunol. 30, 601\u2013614 (2017).","journal-title":"Viral Immunol."},{"key":"182_CR109","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/mt.2010.118","volume":"18","author":"MP Morrow","year":"2010","unstructured":"Morrow, M. P. et al. IL-28B\/IFN-\u03bb3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol. Ther. 18, 1714\u20131723 (2010).","journal-title":"Mol. Ther."},{"key":"182_CR110","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/CVI.00181-10","volume":"17","author":"MP Morrow","year":"2010","unstructured":"Morrow, M. P. et al. Unique Th1\/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in Rhesus Macaques. Clin. Vaccine Immunol. 17, 1493\u20131499 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"182_CR111","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02079-16","volume":"91","author":"MT Baldridge","year":"2017","unstructured":"Baldridge, M. T. et al. Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon \u03bb against norovirus and reovirus. J. Virol. 91, e0207916 (2017).","journal-title":"J. Virol."},{"key":"182_CR112","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/emmm.201100142","volume":"3","author":"O Koltsida","year":"2011","unstructured":"Koltsida, O. et al. IL-28A (IFN-\u03bb 2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol. Med. 3, 348\u2013361 (2011).","journal-title":"EMBO Mol. Med."},{"key":"182_CR113","doi-asserted-by":"crossref","first-page":"E519","DOI":"10.1073\/pnas.1108850108","volume":"108","author":"B Kramer","year":"2011","unstructured":"Kramer, B. et al. Do \u03bb-IFNs IL28A and IL28B act on human natural killer cells? Proc. Natl Acad. Sci. USA 108, E519\u2013E520 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"182_CR114","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/eji.201444903","volume":"45","author":"RA de Groen","year":"2015","unstructured":"de Groen, R. A. et al. IFN-\u03bb-mediated IL-12 production in macrophages induces IFN-\u03b3 production in human NK cells. Eur. J. Immunol. 45, 250\u2013259 (2015).","journal-title":"Eur. J. Immunol."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41577-019-0182-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-019-0182-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41577-019-0182-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:58:24Z","timestamp":1684619904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-019-0182-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":114,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1038\/s41577-019-0182-z","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,14]]},"assertion":[{"value":"16 May 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}